Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
41 hedge funds and large institutions have $12.2M invested in Sio Gene Therapies Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 11 closing their positions.
17% more call options, than puts
Call options by funds: $35K | Put options by funds: $30K
4.46% less ownership
Funds ownership: 29.03% → 24.56% (-4.5%)
15% less funds holding
Funds holding: 48 → 41 (-7)
56% less capital invested
Capital invested by funds: $27.6M → $12.2M (-$15.4M)
59% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 17
64% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Clearline Capital
New York
|
+$148K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$62K |
| 3 |
Two Sigma Investments
New York
|
+$55.1K |
| 4 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
+$35.7K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$13.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
-$2.37M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$494K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$307K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$215K |
| 5 |
Millennium Management
New York
|
-$190K |
SIOX Hedge Fund Activity: Q1 2022 in Review
41 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q1 2022, worth a combined $12.2M — down 56% from $27.6M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of SIOX and 4 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 7 added.
The largest buyer was Clearline Capital, adding an estimated $148K. The largest seller was Privium Fund Management, exiting entirely with an estimated $2.37M sold.
- 41 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q1 2022, down from 48 in Q4 2021.
- Funds reported $12.2M of Sio Gene Therapies Inc. Common Stock stock for Q1 2022, down 56% quarter-over-quarter.
- 4 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q1 2022 and 11 closed out, a net change of -7 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q1 2022 was Clearline Capital, an estimated $148K added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q1 2022 was Privium Fund Management, an estimated $2.37M sold.
Based on aggregated 13F filings for Q1 2022.